The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury
- PMID: 32867310
- PMCID: PMC7503761
- DOI: 10.3390/ijms21176204
The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury
Abstract
Traumatic brain injury (TBI) represents an important problem of global health. The damage related to TBI is first due to the direct injury and then to a secondary phase in which neuroinflammation plays a key role. NLRP3 inflammasome is a component of the innate immune response and different diseases, such as neurodegenerative diseases, are characterized by NLRP3 activation. This review aims to describe NLRP3 inflammasome and the consequences related to its activation following TBI. NLRP3, caspase-1, IL-1β, and IL-18 are significantly upregulated after TBI, therefore, the use of nonspecific, but mostly specific NLRP3 inhibitors is useful to ameliorate the damage post-TBI characterized by neuroinflammation. Moreover, NLRP3 and the molecules associated with its activation may be considered as biomarkers and predictive factors for other neurodegenerative diseases consequent to TBI. Complications such as continuous stimuli or viral infections, such as the SARS-CoV-2 infection, may worsen the prognosis of TBI, altering the immune response and increasing the neuroinflammatory processes related to NLRP3, whose activation occurs both in TBI and in SARS-CoV-2 infection. This review points out the role of NLRP3 in TBI and highlights the hypothesis that NLRP3 may be considered as a potential therapeutic target for the management of neuroinflammation in TBI.
Keywords: NLRP3 inflammasome; SARS-CoV-2; neuroinflammation; pyroptosis; traumatic brain injury.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
NLRP3 inflammasome in traumatic brain injury: Its implication in the disease pathophysiology and potential as a therapeutic target.Life Sci. 2023 Feb 1;314:121352. doi: 10.1016/j.lfs.2022.121352. Epub 2022 Dec 30. Life Sci. 2023. PMID: 36592789 Review.
-
The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target.J Neuroinflammation. 2020 Apr 6;17(1):104. doi: 10.1186/s12974-020-01778-5. J Neuroinflammation. 2020. PMID: 32252777 Free PMC article. Review.
-
A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury.J Neuroinflammation. 2019 Apr 11;16(1):81. doi: 10.1186/s12974-019-1471-y. J Neuroinflammation. 2019. PMID: 30975164 Free PMC article.
-
Targeting the NLRP3 Inflammasome in Severe COVID-19.Front Immunol. 2020 Jun 23;11:1518. doi: 10.3389/fimmu.2020.01518. eCollection 2020. Front Immunol. 2020. PMID: 32655582 Free PMC article. Review.
-
SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9169-9171. doi: 10.26355/eurrev_202009_22867. Eur Rev Med Pharmacol Sci. 2020. PMID: 32965010
Cited by
-
The role of regulatory necrosis in traumatic brain injury.Front Mol Neurosci. 2022 Oct 18;15:1005422. doi: 10.3389/fnmol.2022.1005422. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36329694 Free PMC article. Review.
-
'Comprehensive review of emerging drug targets in traumatic brain injury (TBI): challenges and future scope.Inflammopharmacology. 2024 Oct;32(5):3271-3293. doi: 10.1007/s10787-024-01524-w. Epub 2024 Jul 17. Inflammopharmacology. 2024. PMID: 39023681 Review.
-
Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38/MAPK signaling after TBI and prevent chronic brain dysfunction.Brain Behav Immun. 2023 Feb;108:118-134. doi: 10.1016/j.bbi.2022.11.014. Epub 2022 Nov 24. Brain Behav Immun. 2023. PMID: 36427808 Free PMC article.
-
Interaction of obesity and proteins associated with the NLRP3 inflammasome following mild traumatic brain injury.Sci Rep. 2024 May 3;14(1):10178. doi: 10.1038/s41598-024-61089-0. Sci Rep. 2024. PMID: 38702410 Free PMC article.
-
Contradictory Effects of NLRP3 Inflammasome Regulatory Mechanisms in Colitis.Int J Mol Sci. 2020 Oct 30;21(21):8145. doi: 10.3390/ijms21218145. Int J Mol Sci. 2020. PMID: 33143375 Free PMC article. Review.
References
-
- Bonsack B., Corey S., Shear A., Heyck M., Cozene B., Sadanandan N., Zhang H., Gonzales-Portillo B., Sheyner M., Borlongan C.V. Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury. CNS Neurosci. Ther. 2020;26:603–615. doi: 10.1111/cns.13378. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous